Enzalutamide in the treatment of metastatic castrationally-resistant prostate cancer following previous chemotherapy

Simple item page
dc.contributor.authorRichter Igorcs
dc.contributor.authorDvořák Josefcs
dc.contributor.authorHejzlarová V.cs
dc.contributor.authorBartoš Jiřícs
dc.date.accessioned2018-09-25T12:18:16Z
dc.date.available2018-09-25T12:18:16Z
dc.date.issued2017cs
dc.format.extent5cs
dc.identifier.issn2464-7195cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/31787
dc.language.isoczecs
dc.publisherCurrent Mediacs
dc.publisher.cityPrahacs
dc.relation.ispartofseries0cs
dc.subjectprostate cancercs
dc.subjectmetastasescs
dc.subjectandrogen receptorcs
dc.subjectoveral survivalcs
dc.subjectprogression free survivalcs
dc.subjecttoxicitycs
dc.titleEnzalutamide in the treatment of metastatic castrationally-resistant prostate cancer following previous chemotherapyen
dc.titleEnzalutamid v léčbě metastazujícího kastračně rezistentního karcinomu prostaty po předchozí chemoterapiics
local.citation.epage22-26cs
local.citation.spage22-26cs
local.identifier.publikace5256
local.relation.issue3cs
Files
Collections